Geographic barriers to gynecologic oncology care affects nearly 10% of women
the ONA take:
Access to specialty care for gynecologic cancers is limited in a significant portion of the country, according to a recent study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
The study reveals that 47 states have at least one county located more than 50 miles from the nearest gynecologic oncologist.
The researchers estimate than more than 7,000 women with gynecologic cancers experience distance-related barriers to specialist care.
In addition, referral network-related barriers affect access to specialist care for 15% of women. The study showed that 123 referral networks nationally do not have access to a gynecologic oncologist, and women have to travel outside of the referral network to be connected to a specialist.
The impact limited access to high-quality care has on clinical outcomes is not yet known. The researchers suggest future studies should focus on correlating poor clinical outcomes with geographic factors.
Access to specialty care for gynecologic cancers is limited in a significant portion of the country.
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- G-CSF May Help Preserve Fertility in Male Patients With Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Patients With HER2-enriched Subtype Benefit Most from Dual HER2 Blockade
- Scalp Cooling Reduces Risk of Chemotherapy-Induced Alopecia
- CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|